1. Home
  2. CDP vs RARE Comparison

CDP vs RARE Comparison

Compare CDP & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo COPT Defense Properties of Beneficial Interest

CDP

COPT Defense Properties of Beneficial Interest

HOLD

Current Price

$29.63

Market Cap

3.2B

Sector

Real Estate

ML Signal

HOLD

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

HOLD

Current Price

$36.45

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDP
RARE
Founded
1988
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.2B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
CDP
RARE
Price
$29.63
$36.45
Analyst Decision
Buy
Strong Buy
Analyst Count
7
15
Target Price
$33.29
$85.20
AVG Volume (30 Days)
882.8K
1.3M
Earning Date
10-30-2025
11-04-2025
Dividend Yield
4.11%
N/A
EPS Growth
9.45
N/A
EPS
1.32
N/A
Revenue
$752,757,000.00
$630,598,000.00
Revenue This Year
N/A
$19.09
Revenue Next Year
$4.48
$20.62
P/E Ratio
$22.46
N/A
Revenue Growth
0.43
20.63
52 Week Low
$23.92
$25.81
52 Week High
$33.49
$50.00

Technical Indicators

Market Signals
Indicator
CDP
RARE
Relative Strength Index (RSI) 51.80 63.79
Support Level $29.59 $33.16
Resistance Level $30.99 $34.77
Average True Range (ATR) 0.58 1.55
MACD -0.02 0.34
Stochastic Oscillator 46.85 88.32

Price Performance

Historical Comparison
CDP
RARE

About CDP COPT Defense Properties of Beneficial Interest

COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Share on Social Networks: